The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index; 3 of the 34 sources its claims cite were checked for support.
Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities—2021 Update
Open accessAbstract
This report describes updates to the National Safety Council's Alcohol, Drugs and Impairment Division's recommendations for drug testing in driving under the influence of drug (DUID) cases and motor vehicle fatalities. The updates are based on a survey of drug testing practices in laboratories in the USA and Canada, a comprehensive review of the prior recommendations and data and research on drugs most frequently detected in DUID cases. A consensus meeting was held with representative forensic science practitioners and the authors of this report to update recommendations. No changes were made to the Tier I scope; however, there were changes to cutoffs of some analytes for blood, urine and oral fluid. Due to increased prevalence in DUID cases, trazodone and difluoroethane were added to the Tier II scope. For clarification, Tier I cutoffs reflect free concentrations, and hydrolysis is recommended but not required. The consensus panel concluded that urine is an inferior matrix to blood and oral fluid as it may represent historical use or exposure unrelated to observed impairment; therefore, future iterations of these recommendations will not include urine as a recommended matrix. Laboratories currently testing urine should work with traffic safety partners to encourage the use of blood and oral fluid as more appropriate specimens and adjust their capabilities to provide that testing.
Overview
CoChat Summary
TL;DR
This 2021 update revises the National Safety Council’s Alcohol, Drugs and Impairment Division recommendations for toxicological testing in drug-impaired driving and motor vehicle fatality cases. It retains the Tier I scope, makes selected cutoff changes, adds trazodone and difluoroethane to Tier II, and states that future iterations will no longer include urine as a recommended matrix.
Key findings
- No changes were made to Tier I compound scope; cutoff changes included raising carisoprodol screening/confirmation to 1,000 ng/mL, removing meprobamate urine and oral fluid screening cutoffs, raising norbuprenorphine blood confirmation to 1 ng/mL, and raising fentanyl urine confirmation to 1 ng/mL.
- Trazodone and difluoroethane were added to Tier II due to increased prevalence; Tier II also includes classes such as synthetic cannabinoids, cathinones, novel benzodiazepines, fentanyl analogs, and novel opioids.
- In the 2020 survey of 65 laboratories, 89% tested blood, 63% tested urine, and 3% tested oral fluid; 45% reported a stop-testing policy, with 34% of those stopping at 0.08 g/dL and 41% at 0.10 g/dL.
- Compliance with 2017 blood scope/cutoffs was 12% meeting or exceeding all recommendations, 40% partial compliance with active method development, 19% disagreeing with some aspect, and 44% close to meeting recommendations.
- The consensus panel concluded urine is inferior to blood and oral fluid because it may represent historical use or exposure unrelated to observed impairment; future iterations will not include urine as a recommended matrix.
Methods
- A 2020 SurveyMonkey survey was sent to 325 US and Canadian forensic toxicology laboratory directors; 84 responded, and 65 laboratories completed the survey. Questions covered agency type, staffing, resources, caseload, screening/confirmation technologies, matrices, scope, cutoffs, drug prevalence, and compliance, plus new items on reporting limits, ethanol-based stop-testing, hydrolysis, and urine quantification.
- A virtual consensus meeting was held in July and August 2020 with a subset of survey respondents (n = 10) and authors, representing AL, AZ, CA, CO, FL, IN, MD, MI, NC, NH, NY, OR, PA, TX, and WI. The panel used a modified Delphi method to review the 2020 survey and 2017 recommendations and re-evaluate scope, cutoffs, and Tier I/Tier II designation.
- Survey data were analyzed using SurveyMonkey and Microsoft Excel.
Limitations
- Stated in the paper: laboratories continue to face lack of budget, time, staffing, and instrumentation, which hinders full implementation of the recommendations.
- Stated in the paper: urine is limited as a matrix because drug presence demonstrates only historical drug use or exposure and does not equate to impairment at the time of collection or proximate to driving.
- Evident from the text, not framed by the authors as limitations: the survey had 65 completed responses from 325 invited laboratory directors, relied on self-reported practices, and the consensus panel was a subset of 10 respondents plus authors, which may limit generalizability across all laboratories and jurisdictions.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
3 Valid · 3 Not valid · 14 Not checked · 42 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The rate of diffusion is affected by several factors including lipophilicity of the drug, salivary pH, pKa, molecular size, un-ionized free drug blood concentration and membrane characteristics (8–11).”
§ Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities—2021 Update > Recommendations
What the sources say
- Partly supportedcites [8] Bosker, 2009, Oral fluid testing for drugs of abuse, Clinical Chemistry sourceExperimental — accuracy not yet measured
The Summary (page unavailable) links drug transfer between blood and oral fluid to pKa, lipophilicity, pH differences, and free uncharged drug crossing membranes. It does not address molecular size or membrane characteristics as factors affecting the rate of diffusion, so the full list is not supported by this copy. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [9] Crouch, 2005, Oral fluid collection: the neglected variable in oral fluid testing, Forensic Science International source
- Not checked — no full text of the sourcecites [10] Desrosiers, 2019, Oral fluid drug testing: analytical approaches, issues and interpretation of results, Journal of Analytical Toxicology source
- Not checked — no full text of the sourcecites [11] Drummer, 2006, Drug testing in oral fluid, Clinical Biochemist Reviews
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For confirmation of drugs in urine, GC–MS was used by 62% of laboratories, followed by LC–MS-MS (51%), LC–HRMS (11%), GC–NPD (3%), GC–FID (3%), ELISA (2%) and EMIT (2%).”
§ Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities—2021 Update > Results > Toxicology survey
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thirty-five percent of laboratories report unconfirmed screening results.”
§ Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities—2021 Update > Results > Toxicology survey
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Rates of compliance remained the same or increased for cutoffs that had not changed between the 2013 and 2017 recommendations.”
§ Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities—2021 Update > Results > Toxicology survey
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Compounds newly promoted to Tier I from the 2017 recommendations (fentanyl, tramadol, O-desmethyltramadol, buprenorphine and norbuprenorphine) demonstrated compliance of at least 48%.”
§ Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities—2021 Update > Results > Toxicology survey
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
19 more claims
Create a free account to see all 62 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 23
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As of 2021, gas chromatography mass spectrometry (GC/MS) remained the most employed mass spectrometry-based screening method in forensic toxicology laboratories, with liquid chromatography tandem mass spectrometry (LC-MS/MS) following closely behind (35% and 31%, respectively) [20].”
From Evaluation of enzyme-linked immunosorbent assay screening kits for the detection of nitazene analogs (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the rise in HRMS use in screening from 2017 to 2021 demonstrates the shift toward broad, mass spectral-based screening methods.”
From Evaluation of enzyme-linked immunosorbent assay screening kits for the detection of nitazene analogs (2025) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities—2021 Update > Recommendations
“no changes to cutoff or scope requirements for screening assays in blood and urine”
§ Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities—2021 Update > Recommendations
“screening and confirmation cutoffs for carisoprodol were raised to 1,000 ng/mL; screening cutoff for meprobamate in urine and oral fluid were removed”
Citations
Cites
Strengthening Forensic Science in the United States: A Path Forward
Council, N. R. (2009) · CrimRxiv · doi:10.21428/cb6ab371.b2d683d2 · Cited by 1,461
Strengthening forensic science in the United States : a path forward
Policy, L. (2009) · National Academies Press eBooks · Cited by 964
Oral fluid testing for drugs of abuse
Bosker, W. M., & Huestis, M. A. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.108670 · Cited by 378 · cited 1×
“Recent developments within the field of forensic toxicology include increased interest in the use of oral fluid as a specimen for drug detection in impaired driving cases (8).”
BackgroundSelf-citation(2006) · PubMed Central · Cited by 241
Oral fluid collection: the neglected variable in oral fluid testing
Crouch, D. J. (2005) · Forensic Science International · doi:10.1016/j.forsciint.2005.02.028 · Cited by 228
Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013–2016: A Review
Logan, B. K., Mohr, A. L. A., Friscia, M., Krotulski, A. J., Papsun, D. M., Kacinko, S. L., Ropero-Miller, J. D., & Huestis, M. A. (2017) · Journal of Analytical Toxicology · doi:10.1093/jat/bkx031 · Cited by 166 · cited 1×
“NPSs include synthetic cannabinoids, cathinones and “bath salts”, and novel opioids, especially fentanyl analogs (4, 5).”
BackgroundSelf-citationOral fluid drug testing: analytical approaches, issues and interpretation of results
Desrosiers, N. A., & Huestis, M. A. (2019) · Journal of Analytical Toxicology · doi:10.1093/jat/bkz048 · Cited by 123 · cited 1×
“Research shows a good correlation between drug detection in oral fluid and other matrices; however, oral fluid concentrations cannot predict blood concentrations or vice versa (10, 18, 19).”
BackgroundSelf-citationLogan, B. K., D’Orazio, A. L., Mohr, A. L. A., Limoges, J. F., Miles, A. K., Scarneo, C. E., Kerrigan, S., Liddicoat, L. J., Scott, K. S., & Huestis, M. A. (2018) · Journal of Analytical Toxicology · doi:10.1093/jat/bkx082 · Cited by 78 · cited 1×
“The updated recommendations were published in 2018 (6).”
BackgroundSelf-citationRecommendations for Toxicological Investigation of Drug Impaired Driving*
Farrell, L. J., Kerrigan, S., & Logan, B. K. (2007) · Journal of Forensic Sciences · doi:10.1111/j.1556-4029.2007.00516.x · Cited by 62 · cited 1×
“Based on survey results and consensus input from a panel of forensic toxicologists, the first recommendations document was published in 2007 and represented a list of drugs considered essential for scope of testing in these investigations (1).”
BackgroundSelf-citationLogan, B. K., Lowrie, K. J., Turri, J. L., Yeakel, J. K., Limoges, J. F., Miles, A. K., Scarneo, C. E., Kerrigan, S., & Farrell, L. J. (2013) · Journal of Analytical Toxicology · doi:10.1093/jat/bkt059 · Cited by 53 · cited 2×
“Laboratories were asked about their testing practices for Tier II compounds, or compounds that may be emerging, or have regional but not national prevalence in DUID populations (3).”
MethodSelf-citation
Research works printed but not linked: 2
- Substance Abuse and Mental Health Services Administration (SAMHSA), 2019, Mandatory Guidelines for Federal Workplace Drug Testing Programs—Oral/Fluid
- Construction Owners Association of Alberta, 2018, Alcohol and Drug Guidelines and Work Rule
Cited by
Pearlson, G. D., Stevens, M. C., & D'Souza, D. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.689444 · Cited by 72
Palmquist, K. B., Truver, M. T., Shoff, E. N., Krotulski, A. J., & Swortwood, M. J. (2023) · Journal of Forensic Sciences · doi:10.1111/1556-4029.15282 · Cited by 39
“5 (BL, OF) 1 (UR) Recommended (Tier II) [5]”
MethodPapsun, D. M., Chan‐Hosokawa, A., Lamb, M. E., & Logan, B. K. (2023) · Journal of Analytical Toxicology · doi:10.1093/jat/bkad036 · Cited by 25
Self-citationRosendo, L. M., Rosado, T., Oliveira, P., et al. (2022) · Molecules · doi:10.3390/molecules27175503 · Cited by 21
“Urine has similar distribution and higher detection windows in comparison with blood and oral fluid but requires a simpler pre-treatment [16] This sample is widely used in testing for driving under the influence of drugs (DUID) and workplace drug testing [16,17].”
BackgroundCoulter, C., Garnier, M., & Moore, C. M. (2022) · Journal of Analytical Toxicology · doi:10.1093/jat/bkac031 · Cited by 20
Metadata
- Authors
- D’Orazio, A. L., Mohr, A. L. A., Chan-Hosokawa, A., Harper, C., Huestis, M. A., Limoges, J. F., Miles, A. K., Scarneo, C. E., Kerrigan, S., Liddicoat, L. J., Scott, K. S., & Logan, B. K.
- Affiliations
- Fredric Rieders Family Foundation (US)
- NMS Labs, 200 Welsh Road, Horsham, PA 19044, USA
- Alabama Department of Forensic Sciences (US)
- Huestis and Smith Toxicology, LLC, 683 Shore Road, Severna Park, MD 21146, USA
- New York City Police Department (US)
- Wisconsin State Laboratory of Hygiene, 2601 Agriculture Drive, PO Box 7996, Madison, WI 53707-7996, USA
- New England Forensic Toxicology, LLC, PO Box 702, Concord, NH 03302, USA
- Sam Houston State University (US)
- Arcadia University (US)
- Corresponding author
- Logan, Barry K
- ORCID
- Venue
- Journal of Analytical Toxicology
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-06-04
- Volume
- 45
- Issue
- 6
- Pages
- 529-536
- ISSN
- 0146-4760 (ISSN-L)
- 1945-2403
- PMC
- PMC8272528
- OpenAlex
- W3164982881
- Semantic Scholar
- 3d92a4793c31161b4c65b3f88d0b6669fd2f173c
- Cited by
- 60
- References
- 14
- Citations by year
- 2026: 5 · 2025: 15 · 2024: 12 · 2023: 12 · 2022: 12 · 2021: 4
- FWCI
- 6.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Analytical Toxicology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Fredric Rieders Family Foundation
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Physical Sciences › Engineering › Safety, Risk, Reliability and Quality › Traffic and Road Safety
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- drug-impaired driving, traffic fatalities, toxicological investigation, blood samples, oral fluid specimens, urine samples, trazodone, forensic toxicology, drug testing laboratories, specimen selection
- MeSH terms
- Accidents, Traffic, Driving Under the Influence, Automobile Driving, Canada, Pharmaceutical Preparations, Humans, Substance Abuse Detection, Motor Vehicles, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities—2021 Update. https://app.cochat.ai/papers/10.1093/jat/bkab064
- The paper
- D’Orazio, A. L., Mohr, A. L. A., Chan-Hosokawa, A., Harper, C., Huestis, M. A., Limoges, J. F., Miles, A. K., Scarneo, C. E., Kerrigan, S., Liddicoat, L. J., Scott, K. S., & Logan, B. K. (2021). Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities—2021 Update. Journal of Analytical Toxicology. https://doi.org/10.1093/jat/bkab064
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.